Panel Q&A about DIAN-TU Trial 001 Results

Description: Opening remarks from the 2020 Virtual DIAD Family Conference, along with a panel discussion about developments in DIAN-TU Trial 001
Runtime: 01:46:02

Speaker: Eric McDade, DO
Speaker title: DIAN Trials Unit Associate Director
Speaker organization: Washington University in St. Louis

Speaker: Randall Bateman, MD
Speaker title: DIAN Trials Unit Director
Speaker organization: Washington University in St. Louis

Speaker: Tammie L. S. Benzinger, MD, PhD
Speaker title: DIAN and DIAN-TU Imaging Coordinator
Speaker organization: Washington University in St. Louis

Speaker: Maria Carrillo, PhD
Speaker title: Chief Science Officer
Speaker organization: Alzheimer’s Association

Speaker: Anne Fagan, PhD
Speaker title: Biomarker Core Leader
Speaker organization: Washington University in St. Louis

Speaker: Karen C. Holdridge, MPH
Speaker title: Clinical Research Scientist
Speaker organization: Eli Lilly and Company

Speaker: Geoff Kerchner, MD, PhD
Speaker title: Global Development Lead
Speaker organization: Roche

Speaker: Marty Reiswig
Speaker organization: Youngtimers

Event: 2020 Virtual DIAD Family Conference
Year: 2020

Search tags: DIAN-TU-001 Trial, solanezumab, gantenerumab, biomarkers, amyloid plaques, tau tangles, research participation, secondary prevention trial, Cognitive Run-In, public-private partnership, open-label extension, A4 trial, preclinical Alzheimer’s, genetic testing, risk and safety, health insurance, amyloid plaques, tau PET imaging, DIAN-TU NexGen Trials, combination therapy, drug targets, APOE4